Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice.
Yue
H H
HH
Diehl
G E
GE
Winoto
A
A
D011125:Adenomatous Polyposis Coli / Q000235:genetics / Q000473:pathology / Q000503:physiopathology; D025601:Adenomatous Polyposis Coli Protein / Q000235:genetics*; D000818:Animals; D015870:Gene Expression / Q000235:genetics; D006579:Heterozygote; D007414:Intestinal Neoplasms / Q000235:genetics / Q000473:pathology / Q000503:physiopathology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009154:Mutation; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D018124:Receptors, Tumor Necrosis Factor / Q000235:genetics / Q000502:physiology*; D013160:Splenic Neoplasms / Q000235:genetics / Q000473:pathology / Q000503:physiopathology; D013953:Thymus Neoplasms / Q000235:genetics / Q000473:pathology / Q000503:physiopathology*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
D025601:Adenomatous Polyposis Coli Protein; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D018124:Receptors, Tumor Necrosis Factor; C505640:Tnfrsf10b protein, mouse; D016159:Tumor Suppressor Protein p53